Elevated factor VIIa—antithrombin complexes are associated with stroke or cardiovascular death in patients with atrial fibrillation
European Journal of Clinical Investigation · 2025
DOI: 10.1111/eci.70091 ↗At a glance
Journal article in European Journal of Clinical Investigation, 2025. Written by Elżbieta Szczygieł-Pilut and 4 co-authors. Institution: Department of Neurology, St John Paul II Hospital, Kraków, Poland. Major MEDLINE topics: Atrial Fibrillation, Factor VIIa, Stroke, Antithrombins. 46 references. Funded by: Uniwersytet Jagielloński Collegium Medicum.
Topics: Schlaganfall
Abstract (original language)
Background
Atrial fibrillation (AF) is associated with a prothrombotic state. We investigated whether factor VIIa‐antithrombin (FVIIa‐AT) complexes, a marker of tissue factor (TF) exposure, are associated with thromboembolic events in AF.
Methods
In 224 nonvalvular AF patients (66% men, median age 69 years, median CHA 2 DS 2 VASc score 4), 71% on direct oral anticoagulants, we measured FVIIa‐AT complexes, along with endogenous thrombin potential (ETP), von Willebrand factor (VWF) and 8‐isoprostane, reflecting oxidative stress. During a median follow‐up of 53 [interquartile range, IQR 47–57] months, we recorded a composite endpoint: ischemic stroke, systemic thromboembolism or cardiovascular (CV) death.
Results
FVIIa‐AT complexes (median 145 [IQR 125–170] pM) were higher in patients with permanent AF ( p < .001), vascular disease ( p = .02), previous stroke ( p < .001) and smoking ( p = .006) as compared with patients without these comorbidities. FVIIa‐AT correlated with NT‐proBNP ( r = .15, p = .022) and ETP ( r = .25, p < .001). During follow‐up, the composite endpoint was recorded in 30 patients (13.4%, 3.0% per year) including 20 with ischemic stroke (8.9%, 2.0% per year, respectively). Patients with the composite endpoint had 29.2% higher baseline FVIIa‐AT complexes compared with the remainder. Patients with FVIIa‐AT complexes in the top quartile (>170 pM) had an increased risk of the composite endpoint (HR 12.0, 95% CI 5.2–28.0, p < .0001). FVIIa‐AT complexes, along with VWF, remained independently associated with the composite endpoint.
Conclusions
This study is the first to show that high plasma FVIIa‐AT complexes are independently associated with thromboembolic events or CV death in AF, suggesting the need for more potent anticoagulation to suppress the residual TF‐mediated coagulation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, St John Paul II Hospital, Kraków, Poland.
- Department of Biocybernetics and Biomedical Engineering, AGH University, Kraków, Poland.
- Clinical Department of Interventional Cardiology, St John Paul II Hospital, Kraków, Poland.
- Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland.
- Cracow Center for Medical Research and Technology, St John Paul II Hospital, Kraków, Poland.
ORCID profiles: Anetta Undas
Funding
- Uniwersytet Jagielloński Collegium Medicum
Cite
APA
Szczygieł-Pilut, E., Błaż, M., Pociask, E., Paszek, E., & Undas, A. (2025). Elevated factor VIIa—antithrombin complexes are associated with stroke or cardiovascular death in patients with atrial fibrillation. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70091
Vancouver
Szczygieł-Pilut E, Błaż M, Pociask E, Paszek E, Undas A. Elevated factor VIIa—antithrombin complexes are associated with stroke or cardiovascular death in patients with atrial fibrillation. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.70091
BibTeX
@article{SzczygiePilut2025,
author = {Szczygieł-Pilut, Elżbieta and Błaż, Michał and Pociask, Elżbieta and Paszek, Elżbieta and Undas, Anetta},
title = {Elevated factor VIIa—antithrombin complexes are associated with stroke or cardiovascular death in patients with atrial fibrillation},
journal = {European Journal of Clinical Investigation},
year = {2025},
doi = {10.1111/eci.70091}
}
EUVIMED